Mathieu Uzzan

Jan 23, 2025 | onlinelibrary.wiley.com | Mathieu Uzzan |David Laharie

Akiyama et al. reported the real-world effectiveness of three JAK inhibitors in a Japanese multicentre cohort of 602 patients with ulcerative colitis (UC); 228, 215 and 159 patients, respectively, were treated with upadacitinib, filgotinib and tofacitinib [1]. Among these patients, 106 (46%) in the upadacitinib group, 30 (14%) in the filgotinib group and none in the tofacitinib group had prior exposure to another JAK inhibitor.

Sep 5, 2024 | onlinelibrary.wiley.com | Nathan Grellier |CRSA Sorbonne Université |Julien Kirchgesner |Mathieu Uzzan

1 INTRODUCTION Crohn's disease (CD) is a lifelong inflammatory disease affecting an increasing number of patients worldwide.1, 2 All segments of the gastrointestinal tract can be affected. The disease is limited to the terminal ileum in about one-third of the patients at diagnosis with a non-stricturing and non-penetrating disease for most of them.3 However, about 20% of patients have a complicated disease at diagnosis that may lead to early surgery.

Jul 20, 2023 | onlinelibrary.wiley.com | Louis Calméjane |David Laharie |Julien Kirchgesner |Mathieu Uzzan

Infliximab or ciclosporin: Considerations for the choice of treatment As seen previously, infliximab and ciclosporin have both proved effective for the management of ASUC. The selection of second-line therapies can be influenced by clinicians' habits, patients' features, safety, or efficacy concerns. While CNIs can induce a swift response, infliximab is usually favored due to fewer monitoring and better safety profile.